Navigation Links
Drugs for Enlarged Prostate May Raise Risk of Aggressive Cancer
Date:6/10/2011

By Steven Reinberg
HealthDay Reporter

THURSDAY, June 9 (HealthDay News) -- The U.S. Food and Drug Administration is calling for new warning labels on a class of drugs used primarily to treat enlarged prostates, because the medications may raise the risk of developing an aggressive form of prostate cancer.

In a statement released Thursday, the agency said the drugs involved include popular medications sold under the brand names Proscar and Propecia (sold by Merck & Co.) and Avodart and Jalyn (sold by GlaxoSmithKline).

According to the FDA, almost 5 million men were prescribed one of these medications between 2002 and 2009. Of these, nearly 3 million men were between the ages of 50 and 79.

The agency is advising doctors not to start patients on these drugs until prostate cancer -- which can mimic the symptoms of an enlarged prostate -- and other urological conditions have been ruled out.

According to the agency, this new warning is based on the results of two large prostate cancer trials.

Although these trials did not include Propecia, which is prescribed to treat hair loss in men, its label is also being updated. However, the FDA said "the applicability of the Avodart and Proscar studies to Propecia, is currently unknown."

All of these drugs are part of a class of medications called 5-alpha reductase inhibitors (5-ARI). According to the FDA, Proscar, Avodart and Jalyn are approved to treat symptoms of enlarged prostate, while Proscar and Avodart are also approved to reduce the risk of urinary retention or surgery related to an enlarged prostate. Propecia is a lower-dose version of Proscar.

Merck issued a statement Thursday on the FDA ruling.

"Merck stands behind the demonstrated safety and efficacy of Proscar [finasteride, 5mg] and Propecia [finasteride, 1mg]. Both products have been prescribed to millions of men, with Proscar prescribed to those suffering from benign prostatic
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Treatment for Abuse of Anti-Anxiety Drugs Tripled Over 10 Years
2. Two Drugs Shown to Prolong Survival in Advanced Melanoma Cases
3. Epilepsy Drugs Risk of Birth Defects May Be Dose-Dependent
4. Widely Used Heart Drugs Linked to Better Breast Cancer Outcomes
5. Illegal Drugs Easy to Buy on the Internet, U.K. Study Finds
6. CT angiography for low-risk heart patients leads to more drugs and tests without benefit
7. Younger Docs More Likely to Prescribe Drugs for Heart Disease: Study
8. Standard Heart Drugs Wont Ease Pulmonary Hypertension
9. Half of prostate cancers could potentially benefit from new type of cancer drugs, U-M study finds
10. Kids Taking ADHD Drugs at Low Risk for Heart Problems: Study
11. Younger doctors prescribe more drugs to reduce heart risk but offer less lifestyle advice
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drugs for Enlarged Prostate May Raise Risk of Aggressive Cancer
(Date:4/24/2014)... a way to sensitise cancer cells to chemotherapy - ... published today in Cell Reports , could pave ... cells that have become resistant to treatment. , The ... mechanisms behind resistance to chemotherapy drugs like Paclitaxel, often ... Andrew Gilmore, who led the research team at The ...
(Date:4/24/2014)... with the negative and stressful outcomes for parents who ... a life-limiting illness, says a recent study led by ... the challenges are numerous and life-changing and stress levels ... the Waterloo-led research reported positive outcomes as well, a ... the most recent issue of the American Journal ...
(Date:4/24/2014)... managing patients before, during and after colorectal surgery cut ... according to researchers who led a study of the ... enhanced recovery, is easier on patients before surgery, doing ... are typically prescribed. After surgery, patients are encouraged to ... to faster recoveries. , Among findings published in the ...
(Date:4/24/2014)... to be boring and irrelevant, could offer an alternative ... Researcher Dr Milena Furtado, and her team from the ... the heart cell fibroblast is a close relative to ... heart. , In research published today in Circulation ... are unique cells due to their genetic program, and ...
(Date:4/24/2014)... Depression affects more than one out of three ... study released in The Lancet Respiratory Medicine ... symptoms physically rather than mentally. , It is ... mental health and functional outcomes of critical care ... assistant professor of Medicine, and it highlights a ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Boring cells could hold the key to heart disease 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3
... March 9 (HealthDay News) -- A preliminary study reports that people ... drug just three times a week without major ill effects. ... research, and it,s not clear how much the drug would cost ... aside, the study raises the possibility that people with type 2 ...
... Boston, MA A team of researchers at Brigham ... out of every twelve adult smokers have abnormal lung ... of interstitial lung disease which is associated with substantial ... positively associated with smoking, these lung densities were inversely ...
... Nottingham could provide hope for any allergy sufferers who ... their household pet. The team of immunologists led ... of Molecular Medical Sciences, and funded by the charity ... a key role in triggering allergic responses to cat ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, March ... former-smokers develop lung conditions that reduce lung capacity, but leave ... pulmonary disease (COPD), new research shows. In fact, the ... New England Journal of Medicine found that these ...
... sheds light--both literally and figuratively--on the intricate brain ... Stanford University recently used light to activate mouse ... or decrease anxiety-related behaviors. Pinpointing the origin of ... disorders, the most common class of psychiatric disease. ...
... Satellites have been busy this week covering severe weather across ... captured an image of the huge stretch of clouds associated ... its slow march eastward. Earlier this week, NASA,s Tropical Rainfall ... tornadoes over Louisiana. Today the eastern third of ...
Cached Medicine News:Health News:New Drug May Trim Insulin Injections to Just 3 a Week 2Health News:Researchers find smoking may increase risk for lung disease 2Health News:Nottingham scientists identify trigger in cat allergy 2Health News:Lesser Known Lung Diseases Can Strike Smokers, Ex-Smokers 2Health News:Researchers selectively control anxiety pathways in the brain 2Health News:NASA and other satellites keeping busy with this week's severe weather 2Health News:NASA and other satellites keeping busy with this week's severe weather 3Health News:NASA and other satellites keeping busy with this week's severe weather 4Health News:NASA and other satellites keeping busy with this week's severe weather 5
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... NewCardio, Inc. (OTC Bulletin Board: NWCI ... Dr. Samuel George, NewCardio,s Senior Medical Advisor, will present ... dataset, conducted independently by the Cardiac Safety Research Consortium ... on December 9, 2010, at the headquarters of the ...
... The addition of Cimzia® (certolizumab pegol; CZP) to ... response, improved function and reduced disease activity in ... patients reflecting those seen in daily clinical practice ... clinical trial data were presented during the American ...
Cached Medicine Technology:NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 3NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 4New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 2New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 3New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 4New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 5New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 6New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 7New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 8New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 9New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 10
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: